Share >  
Share
Share on Tumblr

Suprax

News »

   latest by relevance
Midcap drug cos to see sales, profit squeeze in Jan-March
Apr 19, 2011 at 18:13 | Source: Reuters
Indian mid-sized drugmakers are expected to report sluggish sales growth in January-March as delayed product approvals and rising operational expenses take a toll on profit margins.
Expect AllerNaze to be launched in FY12: Lupin
Nov 29, 2010 at 14:40 | Source: CNBC-TV18
The December launch of AllerNaze is delayed due to packaging issues, CFO of Lupin S Ramesh said. We have postponed it indefinitely, but we could expect it to get back into action perhaps by the end of next fiscal.
Lupin Q4 net up, sees capex for FY11 at Rs 500cr
May 05, 2010 at 17:51 | Source: CNBC-TV18
Lupin has declared its fourth quarter results. The company's Q4 net profit stands at Rs 220 crore while its net sales came in at Rs 1,291 crore. In an interview with CNBC-TV18, Kamal K Sharma, MD, Lupin spoke on the quarter gone by and the road ahead.
To launch 8 generic products in US in Q3, Q4: Lupin
Nov 24, 2009 at 13:38 | Source: CNBC-TV18
In an interview with CNBC-TV18, S Ramesh, Chief Financial Officer of Lupin, spoke about the company and the latest developments in it.
Lupin cons Net Profit up 53% to Rs 1156 mn
Oct 24, 2008 at 12:07
Lupin Q2FY08-09 consolidated Net Profit up 53% to Rs 1156 Mn, Sales at Rs 9221 Mn up by 36%. International market revenues at Rs. 5449 mn, recorded a rise of 65%. Of these, Formulation Business in Advanced Markets constituted 70% at Rs. 3820 mn. Formulation revenues from domestic market at recorded an increase of 24% to Rs. 3033 mn.
Lupin enters into mktg alliance with ASCEND Therapeutics
Jun 23, 2008 at 17:09
Lupin Ltd. announced today that the Company has entered into a promotion agreement for Suprax 400 mg Tablets with ASCEND Therapeutics, Inc.

Videos »
Expect AllerNaze to be launched in FY12: Lupin
Lupin Q4 net up, sees capex for FY11 at Rs 500cr
To launch 8 generic products in US in Q3, Q4: Lupin
Focus more towards CRAMS biz: Lupin
more »

Photos »

  /  
News across the web »
Local manufacturing can boost margins for Lupin
For a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin's show in the quarter to December was modest. But what was disappointing was the 5% growth in ne...
Jan 26, 2012 at 06:07 | Source: Economic Times
Lupin: Growth across geographies
November 9, 2011: A strong show across different geographies has helped Lupin beat market expectations in the second quarter. The company reported a 24 per cent year-on-year growth in both consolidat...
Nov 09, 2011 at 23:47 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

arcadiastoc
ks82

Platinum Member

498 Followers

Just Posted  

These, along with five product launches (including one oral contracept...

10.23 AM Nov 23rd 2011

Related News »
Buy Lupin; target Rs 633: Nirmal Bang
Adjusting for this, the tax rate stood at 26%. 1) In the branded generic segment, Suprax franchise recorded 30% growth, while Antara’s growth declined 6% against an 18% fall in the fenofibrate market. Prescription share in Antara increased to ...
May 15, 2012 at 09:42 | Source: MoneyControl.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window